Scientists evaluated the safety and immunogenicity of 2 mosaic vaccine regimens in virologically suppressed individuals that had initiated antiretroviral therapy during the chronic phase of infection, exemplifying the majority of people living with HIV-1.
[NPJ Vaccines]
